Dae Ho Lee

机构：Ulsan College, University of Ulsan · ORCID：0000-0002-9749-4638

发表论文 30 篇 · 总被引 719 次 · h-index 9

代表论文

• Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study (2021 · Journal of Clinical Oncology · 被引 256)
• Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 154)
• Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer (2023 · Nature Cancer · 被引 48)
• Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma (2024 · Journal of Clinical Oncology · 被引 41)
• Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B) (2025 · Journal of Clinical Oncology · 被引 17)
• Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study (2024 · ESMO Open · 被引 14)